[en] Cardiac glycosides (CGs) are approved for the treatment of cardiovascular alterations and their known cellular target is the alpha subunit of the sodium (Na(+))/potassium (K(+))-ATPase (NKA). Pharmacologically, they represent a well-known generation of drugs for treating cardiovascular problems, thus allowing the investigation of potential dose-dependent side effects. Interestingly, since the end of the 1960s, epidemiological studies have indicated that anti-cancer effects were associated with the regular use of these compounds. Since then, a large body of evidence has been accumulated on the in vitro and in vivo effects of CGs in various experimental models, thus confirming their selective action on cancer cell proliferation and viability. CGs have the potential for targeted therapeutic applications. Many of the anti-cancer activities of these compounds have been linked to the inhibition of their primary target, the NKA. A number of studies have shown a correlation between the overexpression of specific alpha subunits in cancerous versus non-cancerous cells and cancer cell responsiveness. Other findings have provided evidence of the on-target nature of the ascribed anti-cancer effects. More recently, studies have indicated additional intracellular targets for these agents, whose modulation might be, at least in some instances, unrelated to NKA targeting. These include endosomal trafficking of both NKA and Src kinase, downregulation of pro-survival Mcl-1 and Bcl-xL pro-survival proteins, and immunogenic cell death induction, among others. This research update summarizes the current knowledge about CGs as new, targeted anti-cancer agents, alone or in combination with other chemotherapeutic compounds.
scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.
Bibliography
[1] Prassas, I., Diamandis, E.P., Novel therapeutic applications of cardiac glycosides. Nat. Rev. Drug Discov. 7 (2008), 926–935.
[2] Mijatovic, T., Roland, I., Van Quaquebeke, E., Nilsson, B., Mathieu, A., Van Vynckt, F., et al. The alpha1 subunit of the sodium pump could represent a novel target to combat non-small cell lung cancers. J. Pathol. 212 (2007), 170–179.
[3] Liu, L., Askari, A., Beta-subunit of cardiac Na+-K+-ATPase dictates the concentration of the functional enzyme in caveolae. Am. J. Physiol. Cell Physiol. 291 (2006), C569–C578.
[4] Liang, M., Tian, J., Liu, L., Pierre, S., Liu, J., Shapiro, J., et al. Identification of a pool of non-pumping Na/K-ATPase. J. Biol. Chem. 282 (2007), 10585–10593.
[5] Lai, F., Madan, N., Ye, Q., Duan, Q., Li, Z., Wang, S., et al. Identification of a mutant alpha1 Na/K-ATPase that pumps but is defective in signal transduction. J. Biol. Chem. 288 (2013), 13295–13304.
[7] Cherniavsky Lev, M., Karlish, S.J., Garty, H., Cardiac glycosides induced toxicity in human cells expressing alpha1-, alpha2-, or alpha3-isoforms of Na-K-ATPase. Am. J. Physiol. Cell Physiol. 309 (2015), C126–C135.
[8] Tian, J., Li, X., Liang, M., Liu, L., Xie, J.X., Ye, Q., et al. Changes in sodium pump expression dictate the effects of ouabain on cell growth. J. Biol. Chem. 284 (2009), 14921–14929.
[9] Karpova, L., Eva, A., Kirch, U., Boldyrev, A., Scheiner-Bobis, G., Sodium pump alpha1 and alpha3 subunit isoforms mediate distinct responses to ouabain and are both essential for survival of human neuroblastoma. FEBS J. 277 (2010), 1853–1860.
[10] Lin, Y., Ho, D.H., Newman, R.A., Human tumor cell sensitivity to oleandrin is dependent on relative expression of Na+, K+ -ATPase subunitst. J. Exp. Ther. Oncol. 8 (2010), 271–286.
[11] Lefranc, F., Mijatovic, T., Kondo, Y., Sauvage, S., Roland, I., Debeir, O., et al. Targeting the alpha 1 subunit of the sodium pump to combat glioblastoma cells. Neurosurgery 62 (2008), 211–221 (discussion 21–2).
[12] Novković, V.M., Stanojević, L.P., Cakić, M.D., Palić, R.M., Veljković, V.B., Stanković, M.Z., Extraction of digoxin from fermented woolly foxglove foliage by percolation. Sep. Sci. Technol. 49 (2014), 829–837.
[13] Schoner, W., Scheiner-Bobis, G., Endogenous and exogenous cardiac glycosides: their roles in hypertension, salt metabolism, and cell growth. Am. J. Physiol. Cell Physiol. 293 (2007), C509–C536.
[14] Laursen, M., Gregersen, J.L., Yatime, L., Nissen, P., Fedosova, N.U., Structures and characterization of digoxin- and bufalin-bound Na+, K+-ATPase compared with the ouabain-bound complex. Proc. Natl. Acad. Sci. U. S. A. 112 (2015), 1755–1760.
[15] Katz, A., Lifshitz, Y., Bab-Dinitz, E., Kapri-Pardes, E., Goldshleger, R., Tal, D.M., et al. Selectivity of digitalis glycosides for isoforms of human Na,K-ATPase. J. Biol. Chem. 285 (2010), 19582–19592.
[16] Weigand, K.M., Laursen, M., Swarts, H.G., Engwerda, A.H., Prufert, C., Sandrock, J., et al. Na(+), K(+)-ATPase isoform selectivity for digitalis-like compounds is determined by two amino acids in the first extracellular loop. Chem. Res. Toxicol. 27 (2014), 2082–2092.
[17] Wu, J., Akkuratov, E.E., Bai, Y., Gaskill, C.M., Askari, A., Liu, L., Cell signaling associated with Na(+)/K(+)-ATPase: activation of phosphatidylinositide 3-kinase IA/Akt by ouabain is independent of Src. Biochemistry 52 (2013), 9059–9067.
[18] Van Quaquebeke, E., Simon, G., Andre, A., Dewelle, J., El Yazidi, M., Bruyneel, F., et al. Identification of a novel cardenolide (2″-oxovoruscharin) from Calotropis procera and the hemisynthesis of novel derivatives displaying potent in vitro antitumor activities and high in vivo tolerance: structure-activity relationship analyses. J. Med. Chem. 48 (2005), 849–856.
[19] Juncker, T., Schumacher, M., Dicato, M., Diederich, M., UNBS1450 from Calotropis procera as a regulator of signaling pathways involved in proliferation and cell death. Biochem. Pharmacol. 78 (2009), 1–10.
[20] Cerella, C., Dicato, M., Diederich, M., Assembling the puzzle of anti-cancer mechanisms triggered by cardiac glycosides. Mitochondrion 13 (2013), 225–234.
[21] Slingerland, M., Cerella, C., Guchelaar, H.J., Diederich, M., Gelderblom, H., Cardiac glycosides in cancer therapy: from preclinical investigations towards clinical trials. Invest. New Drugs 31 (2013), 1087–1094.
[22] Muscella, A., Greco, S., Elia, M.G., Storelli, C., Marsigliante, S., Angiotensin II stimulation of Na+/K+ATPase activity and cell growth by calcium-independent pathway in MCF-7 breast cancer cells. J. Endocrinol. 173 (2002), 315–323.
[23] Weidemann, H., “The Lower Threshold” phenomenon in tumor cells toward endogenous digitalis-like compounds: responsible for tumorigenesis?. J. Carcinog., 11, 2012, 2.
[24] Stenkvist, B., Bengtsson, E., Eriksson, O., Holmquist, J., Nordin, B., Westman-Naeser, S., Cardiac glycosides and breast cancer. Lancet, 1, 1979, 563.
[25] Stenkvist, B., Bengtsson, E., Eklund, G., Eriksson, O., Holmquist, J., Nordin, B., et al. Evidence of a modifying influence of heart glucosides on the development of breast cancer. Anal Quant Cytol. 2 (1980), 49–54.
[26] Kometiani, P., Liu, L., Askari, A., Digitalis-induced signaling by Na+/K+-ATPase in human breast cancer cells. Mol. Pharmacol. 67 (2005), 929–936.
[27] Mijatovic, T., Mathieu, V., Gaussin, J.F., De Neve, N., Ribaucour, F., Van Quaquebeke, E., et al. Cardenolide-induced lysosomal membrane permeabilization demonstrates therapeutic benefits in experimental human non-small cell lung cancers. Neoplasia 8 (2006), 402–412.
[28] Mijatovic, T., Jungwirth, U., Heffeter, P., Hoda, M.A., Dornetshuber, R., Kiss, R., et al. The Na+/K+-ATPase is the Achilles heel of multi-drug-resistant cancer cells. Cancer Lett. 282 (2009), 30–34.
[29] Newman, R.A., Yang, P., Hittelman, W.N., Lu, T., Ho, D.H., Ni, D., et al. Oleandrin-mediated oxidative stress in human melanoma cells. J. Exp. Ther. Oncol. 5 (2006), 167–181.
[30] Xie, C.M., Chan, W.Y., Yu, S., Zhao, J., Cheng, C.H., Bufalin induces autophagy-mediated cell death in human colon cancer cells through reactive oxygen species generation and JNK activation. Free Radic. Biol. Med. 51 (2011), 1365–1375.
[31] Chibalin, A.V., Pedemonte, C.H., Katz, A.I., Feraille, E., Berggren, P.O., Bertorello, A.M., Phosphorylation of the catalyic alpha-subunit constitutes a triggering signal for Na+, K+-ATPase endocytosis. J. Biol. Chem. 273 (1998), 8814–8819.
[32] Chibalin, A.V., Zierath, J.R., Katz, A.I., Berggren, P.O., Bertorello, A.M., Phosphatidylinositol 3-kinase-mediated endocytosis of renal Na+, K+-ATPase alpha subunit in response to dopamine. Mol. Biol. Cell 9 (1998), 1209–1220.
[33] Cherniavsky-Lev, M., Golani, O., Karlish, S.J., Garty, H., Ouabain-induced internalization and lysosomal degradation of the Na+/K+-ATPase. J. Biol. Chem. 289 (2014), 1049–1059.
[34] Liu, J., Kesiry, R., Periyasamy, S.M., Malhotra, D., Xie, Z., Shapiro, J.I., Ouabain induces endocytosis of plasmalemmal Na/K-ATPase in LLC-PK1 cells by a clathrin-dependent mechanism. Kidney Int. 66 (2004), 227–241.
[35] Rosen, H., Glukhman, V., Feldmann, T., Fridman, E., Lichtstein, D., Cardiac steroids induce changes in recycling of the plasma membrane in human NT2 cells. Mol. Biol. Cell 15 (2004), 1044–1054.
[36] Radogna, F., Cerella, C., Gaigneaux, A., Christov, C., Dicato, M., Diederich, M., Cell type-dependent ROS and mitophagy response leads to apoptosis or necroptosis in neuroblastoma. Oncogene, 2015.
[37] Wang, Y., Zhan, Y., Xu, R., Shao, R., Jiang, J., Wang, Z., Src mediates extracellular signal-regulated kinase 1/2 activation and autophagic cell death induced by cardiac glycosides in human non-small cell lung cancer cell lines. Mol. Carcinog. 54:suppl. 1 (2015), E26–E34.
[38] Sandilands, E., Frame, M.C., Endosomal trafficking of Src tyrosine kinase. Trends Cell Biol. 18 (2008), 322–329.
[39] Xie, C.M., Liu, X.Y., Yu, S., Cheng, C.H., Cardiac glycosides block cancer growth through HIF-1alpha- and NF-kappaB-mediated Plk1. Carcinogenesis 34 (2013), 1870–1880.
[40] Leu, W.J., Chang, H.S., Chan, S.H., Hsu, J.L., Yu, C.C., Hsu, L.C., et al. Reevesioside A, a cardenolide glycoside, induces anticancer activity against human hormone-refractory prostate cancers through suppression of c-myc expression and induction of G1 arrest of the cell cycle. PLoS One, 9, 2014, e87323.
[41] Denicolai, E., Baeza-Kallee, N., Tchoghandjian, A., Carre, M., Colin, C., Jiglaire, C.J., et al. Proscillaridin A is cytotoxic for glioblastoma cell lines and controls tumor xenograft growth in vivo. Oncotarget. 5 (2014), 10934–10948.
[42] Fujino, T., Kuroda, M., Matsuo, Y., Kubo, S., Tamura, C., Sakamoto, N., et al. Cardenolide glycosides from the seeds of Digitalis purpurea exhibit carcinoma-specific cytotoxicity toward renal adenocarcinoma and hepatocellular carcinoma cells. Biosci. Biotechnol. Biochem. 79 (2015), 177–184.
[43] Einbond, L.S., Wu, H.A., Su, T., Chang, T., Panjikaran, M., Wang, X., et al. Digitoxin activates EGR1 and synergizes with paclitaxel on human breast cancer cells. J. Carcinog., 9, 2010, 10.
[44] Radogna, F., Dicato, M., Diederich, M., Cancer-type-specific crosstalk between autophagy, necroptosis and apoptosis as a pharmacological target. Biochem. Pharmacol. 94 (2015), 1–11.
[45] Wang, Y., Qiu, Q., Shen, J.J., Li, D.D., Jiang, X.J., Si, S.Y., et al. Cardiac glycosides induce autophagy in human non-small cell lung cancer cells through regulation of dual signaling pathways. Int. J. Biochem. Cell Biol. 44 (2012), 1813–1824.
[46] Hu, F., Han, J., Zhai, B., Ming, X., Zhuang, L., Liu, Y., et al. Blocking autophagy enhances the apoptosis effect of bufalin on human hepatocellular carcinoma cells through endoplasmic reticulum stress and JNK activation. Apoptosis 19 (2014), 210–223.
[47] Trenti, A., Grumati, P., Cusinato, F., Orso, G., Bonaldo, P., Trevisi, L., Cardiac glycoside ouabain induces autophagic cell death in non-small cell lung cancer cells via a JNK-dependent decrease of Bcl-2. Biochem. Pharmacol. 89 (2014), 197–209.
[48] Kulikov, A., Eva, A., Kirch, U., Boldyrev, A., Scheiner-Bobis, G., Ouabain activates signaling pathways associated with cell death in human neuroblastoma. Biochim. Biophys. Acta 1768 (2007), 1691–1702.
[49] Juncker, T., Cerella, C., Teiten, M.H., Morceau, F., Schumacher, M., Ghelfi, J., et al. UNBS1450, a steroid cardiac glycoside inducing apoptotic cell death in human leukemia cells. Biochem. Pharmacol. 81 (2011), 13–23.
[50] Cerella, C., Muller, F., Gaigneaux, A., Radogna, F., Viry, E., Chateauvieux, S., et al. Early downregulation of Mcl-1 regulates apoptosis triggered by cardiac glycoside UNBS1450. Cell Death Dis., 6, 2015, e1782.
[51] Pongrakhananon, V., Stueckle, T.A., Wang, H.Y., O'Doherty, G.A., Dinu, C.Z., Chanvorachote, P., et al. Monosaccharide digitoxin derivative sensitize human non-small cell lung cancer cells to anoikis through Mcl-1 proteasomal degradation. Biochem. Pharmacol. 88 (2014), 23–35.
[52] Chan, S.H., Leu, W.J., Hsu, L.C., Chang, H.S., Hwang, T.L., Chen, I.S., et al. Reevesioside F induces potent and efficient anti-proliferative and apoptotic activities through Na(+)/K(+)-ATPase alpha3 subunit-involved mitochondrial stress and amplification of caspase cascades. Biochem. Pharmacol. 86 (2013), 1564–1575.
[53] Muller, F., Cerella, C., Radogna, F., Dicato, M., Diederich, M., Effects of natural products on mcl-1 expression and function. Curr. Med. Chem. 22 (2015), 3447–3461.
[54] Feng, B., Guo, Y.W., Huang, C.G., Li, L., Chen, R.H., Jiao, B.H., 2’-epi-2’-O-Acetylthevetin B extracted from seeds of Cerbera manghas L. induces cell cycle arrest and apoptosis in human hepatocellular carcinoma HepG2 cells. Chem. Biol. Interact. 183 (2010), 142–153.
[55] Mijatovic, T., De Neve, N., Gailly, P., Mathieu, V., Haibe-Kains, B., Bontempi, G., et al. Nucleolus and c-Myc: potential targets of cardenolide-mediated antitumor activity. Mol. Cancer Ther. 7 (2008), 1285–1296.
[56] Mijatovic, T., Op De Beeck, A., Van Quaquebeke, E., Dewelle, J., Darro, F., De Launoit, Y., et al. The cardenolide UNBS1450 is able to deactivate nuclear factor kappaB-mediated cytoprotective effects in human non-small cell lung cancer cells. Mol. Cancer Ther. 5 (2006), 391–399.
[57] Sudol, M., Shields, D.C., Farooq, A., Structures of YAP protein domains reveal promising targets for development of new cancer drugs. Semin. Cell Dev. Biol. 23 (2012), 827–833.
[58] Surovtseva, Y.V., Jairam, V., Salem, A.F., Sundaram, R.K., Bindra, R.S., Herzon, S.B., Characterization of cardiac glycoside natural products as potent inhibitors of DNA double-strand break repair by a whole-cell double immunofluorescence assay. J. Am. Chem. Soc. 138 (2016), 3844–3855.
[59] Kang, M.A., Kim, M.S., Kim, W., Um, J.H., Shin, Y.J., Song, J.Y., et al. Lanatoside C suppressed colorectal cancer cell growth by inducing mitochondrial dysfunction and increased radiation sensitivity by impairing DNA damage repair. Oncotarget 7 (2016), 6074–6087.
[60] Raynal, N.J., Lee, J.T., Wang, Y., Beaudry, A., Madireddi, P., Garriga, J., et al. Targeting calcium signaling induces epigenetic reactivation of tumor suppressor genes in cancer. Cancer Res. 76 (2016), 1494–1505.
[61] Menger, L., Vacchelli, E., Adjemian, S., Martins, I., Ma, Y., Shen, S., et al. Cardiac glycosides exert anticancer effects by inducing immunogenic cell death. Sci. Transl. Med., 4, 2012 143ra99.
[62] Pol, J., Vacchelli, E., Aranda, F., Castoldi, F., Eggermont, A., Cremer, I., et al. Trial watch: immunogenic cell death inducers for anticancer chemotherapy. Oncoimmunology, 4, 2015, e1008866.
[63] Galluzzi, L., Buque, A., Kepp, O., Zitvogel, L., Kroemer, G., Immunological effects of conventional chemotherapy and targeted anticancer agents. Cancer Cell 28 (2015), 690–714.
[64] Chanvorachote, P., Pongrakhananon, V., Ouabain downregulates Mcl-1 and sensitizes lung cancer cells to TRAIL-induced apoptosis. Am. J. Physiol. Cell Physiol. 304 (2013), C263–C272.
[65] Waiwut, P., Inujima, A., Inoue, H., Saiki, I., Sakurai, H., Bufotalin sensitizes death receptor-induced apoptosis via Bid- and STAT1-dependent pathways. Int. J. Oncol. 40 (2012), 203–208.
[66] Lee, D.H., Lee, C.S., Kim, D.W., Ae, J.E., Lee, T.H., Digitoxin sensitizes glioma cells to TRAIL-mediated apoptosis by upregulation of death receptor 5 and downregulation of survivin. Anticancer Drugs 25 (2014), 44–52.
[67] Kulikov, A.V., Slobodkina, E.A., Alekseev, A.V., Gogvadze, V., Zhivotovsky, B., Contrasting effects of cardiac glycosides on cisplatin- and etoposide-induced cell death. Biol. Chem. 397 (2016), 661–670.
[68] Einbond, L.S., Wu, H.A., Sandu, C., Ford, M., Mighty, J., Antonetti, V., et al. Digitoxin enhances the growth inhibitory effects of thapsigargin and simvastatin on ER negative human breast cancer cells. Fitoterapia 109 (2016), 146–154.
[69] Zeino, M., Brenk, R., Gruber, L., Zehl, M., Urban, E., Kopp, B., et al. Cytotoxicity of cardiotonic steroids in sensitive and multidrug-resistant leukemia cells and the link with Na(+)/K(+)-ATPase. J. Steroid Biochem. Mol. Biol. 150 (2015), 97–111.
Similar publications
Sorry the service is unavailable at the moment. Please try again later.
This website uses cookies to improve user experience. Read more
Save & Close
Accept all
Decline all
Show detailsHide details
Cookie declaration
About cookies
Strictly necessary
Performance
Strictly necessary cookies allow core website functionality such as user login and account management. The website cannot be used properly without strictly necessary cookies.
This cookie is used by Cookie-Script.com service to remember visitor cookie consent preferences. It is necessary for Cookie-Script.com cookie banner to work properly.
Performance cookies are used to see how visitors use the website, eg. analytics cookies. Those cookies cannot be used to directly identify a certain visitor.
Used to store the attribution information, the referrer initially used to visit the website
Cookies are small text files that are placed on your computer by websites that you visit. Websites use cookies to help users navigate efficiently and perform certain functions. Cookies that are required for the website to operate properly are allowed to be set without your permission. All other cookies need to be approved before they can be set in the browser.
You can change your consent to cookie usage at any time on our Privacy Policy page.
